Oxygen Biotherapeutics is a specialty pharmaceutical company focused on the development and commercialization of products for critical care patients
Currently, we have two product candidates. Levosimendan is being developed for use in cardiac surgery patients at risk of Low Cardiac Output Syndrome (LCOS). Oxycyte PFC emulsion, is being developed to treat patients with traumatic brain injury (TBI). more...
Oxygen Biotherapeutics’ clinical development is supported by significant preclinical and clinical research. more...
Recent Scientific Publications Highlight Potential Benefits of Levosimendan in Cardiac Surgery and Additional Critical Care Conditions
Publications review potential benefits of levosimendan in various critical care conditions including: cardiac surgery, cardiogenic shock, septic shock, acute renal failure
Wednesday, July 9, 2014 5:30 am PDT
Public Company Information:
MORRISVILLE, N.C.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT) a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today highlighted three recent review articles examining the current clinical use of levosimendan and its potential to address a wide range of critical care conditions. more..
Product Pipeline Development
Levosimendan- Phase 3
Levosimendan is under development in North America for reduction in morbidity and mortality of cardiac surgery patients at risk of low cardiac output syndrome (LCOS). The FDA has granted Fast Track status for levosimendan and has agreed to our Phase 3 clinical trial protocol under a Special Protocol Assessment (SPA). The FDA has provided guidance that a single successful trial will be sufficient to support approval of levosimendan in this indication. Learn more...
Oxycyte® – Phase 2
Phase 1 and 2a clinical development studies were conducted in the United States. The ongoing clinical trial in traumatic brain injury (TBI) is a double-blind, placebo–controlled, dose-escalation study. The first cohort of patients has been successfully completed in Israel and Switzerland with an independent data safety monitoring board approving advancement to the next higher dose. Enrollment in the second cohort, which began in May 2013, is progressing. On February 28, 2014, following submissions of animal data to address the FDA’s prior clinical hold, the FDA announced in a meeting with the Company that we have satisfactorily addressed their safety concerns. The clinical hold was formally lifted on March 7, 2014 when we received written confirmation from the FDA”. Learn more...